Skip to main content
SpringerLink
Log in

Empiric Medical Therapy for Idiopathic Male Infertility

  • Chapter
  • First Online:
Male Infertility

Abstract

The etiology of male infertility can often be identified as either genetic, endocrine, or anatomic, and appropriately targeted therapy or alternative conception treatment options can be provided. Idiopathic male infertility is the diagnosis given to patients when no identifiable male infertility factor is found but abnormalities are still present on semen analysis, and this condition is found in 30–40% of all infertile males.

Hormonal treatment is widely used for empiric treatment of idiopathic male infertility since men with idiopathic male infertility often have hormonal abnormalities not detectable on standard hormone profiles. Some of the hormonal medications used include gonadotropins, androgens, selective estrogen receptor modulators, and aromatase inhibitors. The goal in using these medications is to modify the hypothalamic-pituitary-gonadal axis in order to lead to improved semen parameters and increased pregnancy rates. Off-label use with selective estrogen receptor modulators followed by aromatase inhibitors for the treatment of idiopathic male infertility has yielded the most promising results, but large-scale, randomized controlled trials with pregnancy outcomes data are needed to provide truly convincing benefits.

Increased oxidative stress leading to sperm damage is another possible cause of idiopathic male infertility. Normally excessive reactive oxygen species (ROS) are deactivated or stabilized by the body’s antioxidant system. However, when ROS production occurs unchecked, a state of oxidative stress develops which can damage spermatozoa making them susceptible to lipid peroxidation. Studies have shown that the use of antioxidant therapy to combat increased oxidative stress in patients with idiopathic male infertility can lead to improved semen parameters. However, the variable quality of study design and size, inconsistencies in antioxidant dosing, and lack of consensus on individual versus combination antioxidant therapy make it difficult to provide definitive recommendations on the benefits of antioxidants for empiric treatment of idiopathic male infertility with further large-scale, randomized controlled trials with pregnancy outcomes data needed to determine its true efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siddiq FM, Sigman M. A new look at the medical management of infertility. Urol Clin N Am. 2002;29(4):949–63.

    Article  Google Scholar 

  2. Jungwrith A, Giwercman A, Tournave H, Diemer T, Kopa Z, Dohle G, Krausz C. European association of urology working group on male infertility. European association of urology guidelines on male infertility: the 2012 update. Eur Urol. 2012;62(2):324–32.

    Google Scholar 

  3. Ko EY, Siddiqi K, Brannigan RE, Sabanegh ES. Empirical medical therapy for idiopathic male infertility: a survey of the American Urological Association. J Urol. 2012;187(3):973–8.

    Article  PubMed  Google Scholar 

  4. Badenoch DF, Waxman J, Boorman L, Sidhu B, Moore HD, Holt WV, et al. Administration of a gonadotropin releasing hormone analogue in oligozoospermic infertile males. Acta Endocrinol. 1988;117(2):265–7.

    Article  CAS  Google Scholar 

  5. Crottaz B, Senn A, Reymond MJ, Rey F, Germond M, Gomez F. Follicle-stimulating hormone bioactivity in idiopathic normogonadotropic oligoasthenozoospermia: double-blind trial with gonadotropin-releasing hormone. Fertil Steril. 1992;57(5):1034–43.

    Article  CAS  PubMed  Google Scholar 

  6. Chow VD, Jarvi KA, Buckspan M, Barry-Longley T, Zini A. Intranasal gonadotropin-releasing hormone (GnRH) therapy for men with idiopathic infertility: GnRH stimulation test may predict response to treatment. Fertil Steril. 2000;74(3):605–6.

    Article  CAS  PubMed  Google Scholar 

  7. Kumar R, Gautam G, Gupta NP. Drug therapy for idiopathic male infertility: rationale versus evidence. J Urol. 2006;176(4):1307–12.

    Article  CAS  PubMed  Google Scholar 

  8. Paradisi R, Busacchi P, Seracchioli R, Porcu E, Venturoli S. Effects of high doses of recombinant human follicle-stimulating hormone in the treatment of male factor infertility: results of a pilot study. Fertil Steril. 2006;86(3):728–31.

    Article  CAS  PubMed  Google Scholar 

  9. Colacurci N, Monti MG, Fornaro F, Izzo G, Izzo P, Trotta C, et al. Recombinant human FSH reduces sperm DNA fragmentation in men with idiopathic oligoasthenoteratozoospermia. J Androl. 2011;33(4):588–93.

    Article  CAS  PubMed  Google Scholar 

  10. Attia AM, Abou-Setta AM, Al-Inany HG. Gonadotrophins for idiopathic male factor subfertility. Cochrane Database Syst Rev. 2013;(8):CD005071.

    Google Scholar 

  11. Neumann F, Diallo F, Hasan S, Schenck B, Traore I. The influence of pharmaceutical compounds on male fertility. Andrologia. 1976;8(3):203–35.

    Article  CAS  PubMed  Google Scholar 

  12. Samplaski MK, Loai Y, Wong K, Lo KC, Grober ED, Jarvi KA. Testosterone use in the male infertility population: prescribing patterns and effects on semen and hormonal parameters. Fertil Steril. 2014;101(1):64–9.

    Article  CAS  PubMed  Google Scholar 

  13. Gregoriou O, Papadias C, Gargaropoulos A, Konidaris S, Kontogeorgi Z, Kalampokas E. Treatment of idiopathic infertility with testosterone undecanoate. A double blind study. Clin Exp Obstet Gynecol. 1993;20(1):9–12.

    CAS  PubMed  Google Scholar 

  14. Jung JH, Seo JT. Empirical medical therapy in idiopathic male infertility: promise or panacea? Clin Exp Reprod Med. 2014;41(3):108.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Ramasamy R, Osterberg E, Bernie A. Risks of testosterone replacement therapy in men. Indian J Urol. 2014;30(1):2.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Sabanegh E, Tadros N. Empiric medical therapy with hormonal agents for idiopathic male infertility. Indian J Urol. 2017;33(3):194.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Patankar SS, Kaore SB, Sawane MV. Effect of clomiphene citrate on sperm density in male partners of infertile couples. Indian J Physiol Pharmacol. 2007;51(3):195–8.

    CAS  PubMed  Google Scholar 

  18. Moradi M, Moradi A, Alemi M, Ahmadnia H, Abdi H, Ahmadi A, et al. Safety and efficacy of clomiphene citrate and L-carnitine in idiopathic male infertility: a comparative study. Urol J. 2010;7:188–93.

    PubMed  Google Scholar 

  19. Çakan M, Aldemir M, Topcuoglu M, Altuğ U. Role of testosterone/estradiol ratio in predicting the efficacy of tamoxifen citrate treatment in idiopathic oligoasthenoteratozoospermic men. Urol Int. 2009;83(4):446–51.

    Article  CAS  PubMed  Google Scholar 

  20. Nada EA, Taieb MAE, Ibrahim HM, AE-RAA S. Efficacy of tamoxifen andl-carnitine on sperm ultrastructure and seminal oxidative stress in patients with idiopathic oligoasthenoteratozoospermia. Andrologia. 2014;47(7):801–10.

    Article  CAS  PubMed  Google Scholar 

  21. Tang KF, Xing Y, Wu CY, Liu RZ, Wang XY, King JP. Tamoxifen combined with coenzyme Q10 for idiopathic oligoasthenospermia. Zhonghua Nan Ke Xue. 2011;17:615–8. Chinese.

    CAS  PubMed  Google Scholar 

  22. Vandekerckhove P, Lilford R, Vail A, Hughes E, Hafez M. Clomiphene or tamoxifen for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev. 2000;(2):CD000151.

    Google Scholar 

  23. Chua ME, Escusa KG, Luna S, Tapia LC, Dofitas B, Morales M. Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis. Andrology. 2013;1(5):749–57.

    Article  CAS  PubMed  Google Scholar 

  24. Hussein A, Ozgok Y, Ross L, Niederberger C. Clomiphene administration for cases of nonobstructive azoospermia: a multicenter study. J Androl. 2005;26(6):787–91.

    Article  CAS  PubMed  Google Scholar 

  25. Weedin JW, Bennett RC, Fenig DM, Lamb DJ, Lipshultz LI. Early versus late maturation arrest: reproductive outcomes of testicular failure. J Urol. 2011;186(2):621–6.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Moein M-R, Tabibnejad N, Ghasemzadeh J. Beneficial effect of tamoxifen on sperm recovery in infertile men with nonobstructive azoospermia. Andrologia. 2011;44:194–8.

    Article  CAS  PubMed  Google Scholar 

  27. Raman J, Schlegel P. Aromatase inhibitors for male infertility. J Urol. 2002;167(2):624–9.

    Article  CAS  PubMed  Google Scholar 

  28. Pavlovich CP, King P, Goldstein M, Schlegel PN. Evidence of a treatable Endocrinopathy in infertile men. J Urol. 2001;165:837–41.

    Article  CAS  PubMed  Google Scholar 

  29. Clark RV, Sherins RJ. Treatment of men with idiopathic Oligozoospermic infertility using the aromatase inhibitor, Testolactone results of a double-blinded, randomized, placebo-controlled trial with crossover. J Androl. 1989;10(3):240–7.

    Article  CAS  PubMed  Google Scholar 

  30. Saylam B, Efesoy O, Çayan S. The effect of aromatase inhibitor letrozole on body mass index, serum hormones, and sperm parameters in infertile men. Fertil Steril. 2011;95(2):809–11.

    Article  CAS  PubMed  Google Scholar 

  31. Gregoriou O, Bakas P, Grigoriadis C, Creatsa M, Hassiakos D, Creatsas G. Changes in hormonal profile and seminal parameters with use of aromatase inhibitors in management of infertile men with low testosterone to estradiol ratios. Fertil Steril. 2012;98(1):48–51.

    Article  CAS  PubMed  Google Scholar 

  32. Cavallini G, Biagiotti G, Bolzon E. Multivariate analysis to predict letrozole efficacy in improving sperm count of non-obstructive azoospermic and cryptozoospermic patients: a pilot study. Asian J Androl. 2013;15(6):806–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Shoshany O, Abhyankar N, Mufarreh N, Daniel G, Niederberger C. Outcomes of anastrozole in oligozoospermic hypoandrogenic subfertile men. Fertil Steril. 2017;107(3):589–94.

    Article  CAS  PubMed  Google Scholar 

  34. Agarwal A, Majzoub A. Antioxidant therapy in idiopathic oligoasthenoteratozoospermia. Indian J Urol. 2017;33(3):207.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Aitken RJ, Clarkson JS, Fishel S. Generation of reactive oxygen species, lipid peroxidation, and human sperm function. Biol Reprod. 1989;41(1):183–97.

    Article  CAS  PubMed  Google Scholar 

  36. Agarwal A, Sharma R, Nallella K, Thomasjr A, Alvarez J, Sikka S. Reactive oxygen species as an independent marker of male factor infertility. Fertil Steril. 2006;86(4):878–85.

    Article  CAS  PubMed  Google Scholar 

  37. Tremellen K. Oxidative stress and male infertility—a clinical perspective. Hum Reprod Update. 2008;14(3):243–58.

    Article  CAS  PubMed  Google Scholar 

  38. Agarwal A, Saleh RA, Bedaiwy MA. Role of reactive oxygen species in the pathophysiology of human reproduction. Fertil Steril. 2003;79(4):829–43.

    Article  PubMed  Google Scholar 

  39. Mora-Esteves C, Shin D. Nutrient supplementation: improving male fertility fourfold. Semin Reprod Med. 2013;31(04):293–300.

    Article  PubMed  Google Scholar 

  40. Raijmakers MT, Roelofs HM, Steegers EA, Steegers-Theunissen RP, Mulder TP, Knapen MF, et al. Glutathione and glutathione S-transferases A1-1 and P1-1 in seminal plasma may play a role in protecting against oxidative damage to spermatozoa. Fertil Steril. 2003;79(1):169–72.

    Article  PubMed  Google Scholar 

  41. Ochseedorf FR, Buhl R, Bastlein A, Beschmann H. Glutathione le spermatozoa and seminal plasma of infertile men. Hum Reprod. 1998;13(2):353–9.

    Article  Google Scholar 

  42. Lenzi A, Lombardo F, Gandini L, Culasso F, Dondero F. Glutathione therapy for male infertility. Arch Androl. 1992;29(1):65–8.

    Article  CAS  PubMed  Google Scholar 

  43. Thérond P, Auger J, Legrand A, Jouannet P. α-Tocopherol in human spermatozoa and seminal plasma: relationships with motility, antioxidant enzymes and leukocytes. Mol Hum Reprod. 1996;2(10):739–44.

    Article  PubMed  Google Scholar 

  44. Rolf C. Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study. Hum Reprod. 1999;14(4):1028–33.

    Article  CAS  PubMed  Google Scholar 

  45. Chen XF, Li Z, Ping P, Dai JC, Zhang FB, Shang XJ. Efficacy of natural vitamin E on oligospermia and asthenospermia: a prospective multi-centered randomized controlled study of 106 cases. Zhonghua Nan Ke Xue. 2012;18:428–31.

    PubMed  Google Scholar 

  46. Showell MG, Mackenzie-Proctor R, Brown J, Yazdani A, Stankiewicz MT, Hart RJ. Antioxidants for male subfertility. Cochrane Database Syst Rev. 2014;12:CD007411. https://doi.org/10.1002/14651858.CD007411.pub3.

    Article  Google Scholar 

  47. Fraga CG, Motchnik PA, Shigenaga MK, Helbock HJ, Jacob RA, Ames BN. Ascorbic acid protects against endogenous oxidative DNA damage in human sperm. Proc Natl Acad Sci. 1991;88(24):11003–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Akmal M, Qadri J, Al-Waili NS, Thangal S, Haq A, Saloom KY. Improvement in human semen quality after Oral supplementation of vitamin C. J Med Food. 2006;9(3):440–2.

    Article  CAS  PubMed  Google Scholar 

  49. Ahmed SD, Karira KA, Jagdesh, Ahsan S. Role of L-carnitine in male infertility. J Pakistan Med Assoc. 2011;61(8):732–6.

    Google Scholar 

  50. Sigman M, Glass S, Campagnone J, Pryor JL. Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertil Steril. 2006;85(5):1409–14.

    Article  PubMed  Google Scholar 

  51. Galimov SN, Gromenko DS, Galimova EF, Gromenko L, Iskhakov IR. Effects of L- carnitine on ejaculate parameters in males from infertile couples. Urologia. 2012;1:47–51. Russian.

    Google Scholar 

  52. Garg H, Kumar R. Empirical drug therapy for idiopathic male infertility: what is the new evidence? Urology. 2015;86(6):1065–75.

    Article  PubMed  Google Scholar 

  53. Talevi R, Barbato V, Fiorentino I, Braun S, Longobardi S, Gualtieri R. Protective effects of in vitro treatment with zinc, d-aspartate and coenzyme q10 on human sperm motility, lipid peroxidation and DNA fragmentation. Reprod Biol Endocrinol. 2013;11(1):81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Nadjarzadeh A, Shidfar F, Amirjannati N, Vafa MR, Motevalian SA, Gohari MR, et al. Effect of coenzyme Q10 supplementation on antioxidant enzymes activity and oxidative stress of seminal plasma: a double-blind randomised clinical trial. Andrologia. 2013;46(2):177–83.

    Article  CAS  PubMed  Google Scholar 

  55. Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S. Effects of the reduced form of coenzyme Q10 (Ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. J Urol. 2012;188(2):526–31.

    Article  CAS  PubMed  Google Scholar 

  56. Lafuente R, González-Comadrán M, Solà I, López G, Brassesco M, Carreras R, et al. Coenzyme Q10 and male infertility: a meta-analysis. J Assist Reprod Genet. 2013;30(9):1147–56.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Oeda T, Henkel R, Ohmori H, Schill W-B. Scavenging effect of N-acetyl-L-cysteine against reactive oxygen species in human semen: a possible therapeutic modality for male factor infertility? Andrologia. 2009;29(3):125–31.

    Article  Google Scholar 

  58. Ciftci H, Verit A, Savas M, Yeni E, Erel O. Effects of N-acetylcysteine on semen parameters and oxidative/antioxidant status. Urology. 2009;74(1):73–6.

    Article  PubMed  Google Scholar 

  59. Noack-Füller G, Beer C, Seibert H. Cadmium, lead, selenium, and zinc in semen of occupationally unexposed men. Andrologia. 1993;25(1):7–12.

    Article  PubMed  Google Scholar 

  60. Safarinejad MR, Safarinejad S. Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. J Urol. 2009;181(2):741–51.

    Article  CAS  PubMed  Google Scholar 

  61. Tikkiwal M, Ajmera RL, Mathur NK. Effect of zinc administration on seminal zinc and fertility of oligospermic males. Indian J Physiol Pharmacol. 1987;31:30–4.

    CAS  PubMed  Google Scholar 

  62. Omu A, Al-Azemi M, Kehinde E, Anim J, Oriowo M, Mathew T. Indications of the mechanisms involved in improved sperm parameters by zinc therapy. Med Princ Pract. 2008;17(2):108–16.

    Article  CAS  PubMed  Google Scholar 

  63. Agarwal A, Sekhon L. Oxidative stress and antioxidants for idiopathic oligoasthenoteratospermia: is it justified? Indian J Urol. 2011;27(1):74.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Gupta NP, Kumar R. Lycopene therapy in idiopathic male infertility – a preliminary report. Int Urol Nephrol. 2002;34:369–72.

    Article  CAS  PubMed  Google Scholar 

  65. Tournaye H, Steirteghem ACV, Devroey P. Pentoxifylline in idiopathic male-factor infertility: a review of its therapeutic efficacy after oral administration. Hum Reprod. 1994;9(6):996–1000.

    Article  CAS  PubMed  Google Scholar 

  66. Závaczki Z, Szöllõsi J, Kiss SA, Koloszár S, Fejes I, Kovács L, et al. Magnesium-orotate supplementation for idiopathic infertile male patients: a randomized, placebo-controlled clinical pilot study. Magnes Res. 2003;16(2):131–6.

    PubMed  Google Scholar 

  67. Stanislavov R, Nikolova V, Rohdewald P. Improvement of seminal parameters with Prelox®: a randomized, double-blind, placebo-controlled, cross-over trial. Phytother Res. 2009;23(3):297–302.

    Article  CAS  PubMed  Google Scholar 

  68. Alahmar AT. The effects of oral antioxidants on the semen of men with idiopathic oligoasthenoteratozoospermia. Clin Exp Reprod Med. 2018;45(2):57.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Abad C, Amengual MJ, Gosálvez J, Coward K, Hannaoui N, Benet J, et al. Effects of oral antioxidant treatment upon the dynamics of human sperm DNA fragmentation and subpopulations of sperm with highly degraded DNA. Andrologia. 2013;45(3):211–6.

    Article  CAS  PubMed  Google Scholar 

  70. Busetto GM, Koverech A, Messano M, Antonini G, De Berardinis E, Gentile V. Prospective open-label study on the efficacy and tolerability of a combination of nutritional supplements in primary infertile patients with idiopathic asthenoteratozoospermia. Arch Ital Urol Androl. 2012;84:137–40.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Rutgers New Jersey Medical School, Newark, NJ, USA

    Tejash Shah

  2. Department of Urology, Hackensack University Medical Center, Hackensack, NJ, USA

    David Shin

  3. Hackensack Meridian School of Medicine at Seton Hall University, Nutley, NJ, USA

    David Shin

Authors
  1. Tejash Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Shin .

Editor information

Editors and Affiliations

  1. PUR Clinic, University of Central Florida (UCF), Clermont, FL, USA

    Sijo J. Parekattil

  2. ANDROFERT and State University of Campinas (UNICAMP), Campinas, Brazil

    Sandro C. Esteves

  3. Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA

    Ashok Agarwal

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Shah, T., Shin, D. (2020). Empiric Medical Therapy for Idiopathic Male Infertility. In: Parekattil, S., Esteves, S., Agarwal, A. (eds) Male Infertility. Springer, Cham. https://doi.org/10.1007/978-3-030-32300-4_71

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-32300-4_71

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-32299-1

  • Online ISBN: 978-3-030-32300-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation